New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
07:44 EDTINCY, LLYIncyte weakness creates buying opportunity, says Oppenheimer
After Incyte (INCY) and partner Eli Lilly (LLY) reported Phase IIb results for their baricitinib in rheumatoid arthritis, Oppenheimer expects the drug to be approved in 2015-2016. The firm thinks the baricitinib program is doing well, and it maintains a $23 price target and Outperform rating on Incyte.
News For INCY;LLY From The Last 14 Days
Check below for free stories on INCY;LLY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2014
17:37 EDTLLYFDA grants tentative approval for Lilly, Boehringer Basaglar insulin
Subscribe for More Information
11:41 EDTLLYCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 11, 2014
11:58 EDTLLYMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use